Netherlands Pharmaceuticals & Healthcare Report Q1 2015 - New Market Study Published

Despite the Dutch economy expanding during the second quarter of 2014 at a time were the broader Eurozone have slowed, we believe the Netherlands ' patented and generic drugmakers face difficult challenges over the coming years. The government will likely remain committed to reduce drug prices as it tries to cope with the healthcare demands of a growing aging population. This coupled with a patent cliff along with health insurers looking to include cheaper generic medicines into their policies, keeps our outlook for the market subdued.

Headline Expenditure Projections

* Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.92bn (USD7.93bn) in 2014; -2.8% in local currency terms and -1.3% in US dollar terms.
* Healthcare: EUR70.37bn (USD92.89bn) in 2013 to EUR71.34bn (USD95.59bn) in 2014; 1.4% in local currency terms and 2.9% in US dollar terms.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Indices (RRIs) for the 15 key Western European markets, remaining 12th for Q115. The country fell from eighth in Q413. At 65.1, its overall RRI score remains slightly below the regional average of 68. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down its overall standing.

Full Report Details at
- http://www.fastmr.com/prod/912369_netherlands_pharmaceuticals_healthcare_report_q1.aspx?afid=301

Key Trends And Developments

October

* to-BBB has reported significant additions to complete its new management team in addition to changing its name from to-BBB technologies to BBB Therapeutics. Dr Ferdinand Massari and Dr Pericles Calias have joined BBB as Chief Medical Officer and Chief Scientific Officer. Completing the management team are recently appointed CEO Dr Anders Harfstrand, CFO Leon Kruimer and Chief Business Officer Dr Carlos de...

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Netherlands to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Ukraine Pharmaceuticals & Healthcare Report Q1 2015